Publications

Notable Recent Publications

These are some recent publications which give a flavour of the research from the Barclay lab. For a complete list of publications, please see below.

Species difference in ANP32A underlies influenza A virus polymerase host restriction. Nature (2016).
Jason S. Long, Efstathios S. Giotis, Olivier Moncorgé, Rebecca Frise, Bhakti Mistry, Joe James, Mireille Morisson, Munir Iqbal, Alain Vignal, Michael A. Skinner & Wendy S. Barclay

This paper identified a key factor that explained why the polymerases from avian influenza viruses are restricted in humans.  For more, please see the associated New and Views.

See our latest ANP32 papers here: eLIFE, Journal of Virology, Journal of Virology.

The mechanism of resistance to favipiravir in influenza. PNAS (2018).
Daniel H. Goldhill, Aartjan J. W. te Velthuis, Robert A. Fletcher, Pinky Langat, Maria Zambon, Angie Lackenby & Wendy S. Barclay

This paper showed how influenza could evolve resistance to favipiravir, an antiviral that may be used to treat influenza. The residue that mutated to give resistance was highly conserved suggesting that the mechanism of resistance may be applicable to other RNA viruses.

Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice. Plos Path. (2018).
Hui Li*, Konrad C. Bradley*, Jason S. Long, Rebecca Frise, Jonathan W. Ashcroft, Lorian C. Hartgroves, Holly Shelton, Spyridon Makris, Cecilia Johansson, Bin Cao & Wendy S. Barclay

Why do avian influenza viruses like H5N1 cause such severe disease in humans? This paper demonstrated that H5N1 viruses replicate better than human viruses in myeloid cells from mice leading to a cytokine storm and more severe disease.

Citation

BibTex format

@article{Ward:2021:10.1038/s41467-021-21237-w,
author = {Ward, H and Atchison, C and Whitaker, M and Ainslie, KEC and Elliott, J and Okell, L and Redd, R and Ashby, D and Donnelly, C and Barclay, W and Darzi, A and Cooke, G and Riley, S and Elliott, P},
doi = {10.1038/s41467-021-21237-w},
journal = {Nature Communications},
pages = {1--8},
title = {SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic.},
url = {http://dx.doi.org/10.1038/s41467-021-21237-w},
volume = {12},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - England has experienced a large outbreak of SARS-CoV-2, disproportionately affecting people from disadvantaged and ethnic minority communities. It is unclear how much of this excess is due to differences in exposure associated with structural inequalities. Here we  report from the REal-time Assessment of Community Transmission-2 (REACT-2) national  study of over 100,000 people. After adjusting for test characteristics and re-weighting to the population, overall antibody prevalence is 6.0% (95% CI: 5.8-6.1). An estimated 3.4 million people had developed antibodies to SARS-CoV-2 by mid-July 2020. Prevalence is two- to three-fold higher among health and care workers compared with non-essential workers, and in people of Black or South Asian than white ethnicity, while age- and sex-specific infection  fatality ratios are similar across ethnicities. Our results indicate that higher hospitalisation and  mortality from COVID-19 in minority ethnic groups may reflect higher rates of infection  rather than differential experience of disease or care.
AU  - Ward,H
AU  - Atchison,C
AU  - Whitaker,M
AU  - Ainslie,KEC
AU  - Elliott,J
AU  - Okell,L
AU  - Redd,R
AU  - Ashby,D
AU  - Donnelly,C
AU  - Barclay,W
AU  - Darzi,A
AU  - Cooke,G
AU  - Riley,S
AU  - Elliott,P
DO  - 10.1038/s41467-021-21237-w
EP  - 8
PY  - 2021///
SN  - 2041-1723
SP  - 1
TI  - SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic.
T2  - Nature Communications
UR  - http://dx.doi.org/10.1038/s41467-021-21237-w
UR  - https://www.nature.com/articles/s41467-021-21237-w
UR  - http://hdl.handle.net/10044/1/85566
VL  - 12
ER  -
Download